公开(公告)号：US20230265218A1

公开(公告)日：2023-08-24

申请号：US18172987

申请日：2023-02-22

Applicant: Xencor, Inc. ,  Janssen Biotech, Inc.

Inventor： John R. Desjarlais ,  Gregory Moore ,  Michael Hedvat ,  Juan Diaz ,  Veronica Gusti Zeng ,  Matthew Adam Dragovich ,  Joseph Erhardt ,  Theresa McDevitt ,  Fouad Moussa ,  Pankaj Seth ,  Fei Shen ,  Adam Zwolak

IPC: C07K16/46

CPC classification number: C07K16/468 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/622

Abstract: Provided herein are novel anti-CD28×anti-PSMA antibodies and methods of using such antibodies for the treatment of PSMA-associated cancers. Subject anti-CD28×anti-PSMA antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and PSMA on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3×anti-PSMA antibodies) for the treatment of prostate cancers.

公开(公告)号：US11952411B2

公开(公告)日：2024-04-09

申请号：US17405872

申请日：2021-08-18

Applicant: JANSSEN BIOTECH, INC.

Inventor： Adam Zwolak ,  Szeman Chan ,  Rajkumar Ganesan

IPC: C07K14/705 ,  A61K38/00 ,  A61P37/04 ,  C07K14/765

CPC classification number: C07K14/70575 ,  A61P37/04 ,  C07K14/765 ,  A61K38/00 ,  C07K2319/30 ,  C07K2319/31 ,  C07K2319/74

Abstract: Described herein are compositions and kits that comprise an engineered TL1A ligand that displays high stability, minimal binding to decoy receptor DcR3 while retaining functional activity via binding to its cell surface receptor, DR3, and the ability to activate T cells in vitro and in vivo. Methods of making an engineered TL1A ligand and methods of treating a disease or disorder in a subject by administering an engineered TL1A ligand are also provided.

公开(公告)号：US20220411504A1

公开(公告)日：2022-12-29

申请号：US17330462

申请日：2021-05-26

Applicant: Janssen Biotech, Inc.

Inventor： Raymond Brittingham ,  Scott R. Brodeur ,  Rajkumar Ganesan ,  Jaclyn Hoover ,  Steven A. Jacobs ,  Colleen M. Kane ,  Jinquan Luo ,  Sanjaya Singh ,  Fang Yi ,  Adam Zwolak ,  Triveni K. Bhatt ,  Michael Dennis Feldkamp ,  Sherry Lynn La Porte

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/30 ,  C07K16/42

Abstract: The disclosure provides antigen binding domains that bind cluster of differentiation 3 (CD3) protein, comprising the antigen binding domains that bind CD3ε, polynucleotides encoding them, vectors, host cells, methods of making and using them.

公开(公告)号：US12084501B2

公开(公告)日：2024-09-10

申请号：US17701764

申请日：2022-03-23

Applicant: Janssen Biotech, Inc.

Inventor： Adam Zwolak ,  Raymond Brittingham ,  Scott R. Brodeur ,  Rajkumar Ganesan ,  Sherry Lynn La Porte ,  Jinquan Luo ,  Fang Yi ,  Colleen M. Kane ,  Triveni K. Bhatt

IPC: C07K16/28 ,  C07K16/46 ,  C12N15/85 ,  A61K39/00

CPC classification number: C07K16/2809 ,  C07K16/468 ,  C12N15/85 ,  A61K2039/507 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/622

Abstract: The disclosure provides antigen binding domains that bind cluster of differentiation 3 (CD3) protein, comprising the antigen binding domains that bind CD3ε, polynucleotides encoding them, vectors, host cells, methods of making and using them.

公开(公告)号：US20240218082A1

公开(公告)日：2024-07-04

申请号：US18440860

申请日：2024-02-13

Applicant: Xencor, Inc. ,  Janssen Biotech, Inc.

Inventor： John R. Desjarlais ,  Gregory Moore ,  Michael Hedvat ,  Juan Diaz ,  Veronica Gusti Zeng ,  Matthew Adam Dragovich ,  Joseph Erhardt ,  Theresa McDevitt ,  Fouad Moussa ,  Pankaj Seth ,  Fei Shen ,  Adam Zwolak

IPC: C07K16/46 ,  C07K16/28 ,  C07K16/30

CPC classification number: C07K16/468 ,  C07K16/2818 ,  C07K16/3069 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/622

Abstract: Provided herein are novel anti-CD28 x anti-PSMA antibodies and methods of using such antibodies for the treatment of PSMA-associated cancers. Subject anti-CD28 x anti-PSMA antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and PSMA on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3 x anti-PSMA antibodies) for the treatment of prostate cancers.

公开(公告)号：US20230040715A1

公开(公告)日：2023-02-09

申请号：US17701764

申请日：2022-03-23

Applicant: Janssen Biotech, Inc.

Inventor： Adam Zwolak ,  Raymond Brittingham ,  Scott R. Brodeur ,  Rajkumar Ganesan ,  Sherry Lynn La Porte ,  Jinquan Luo ,  Fang Yi ,  Colleen M. Kane ,  Triveni K. Bhatt

IPC: C07K16/28 ,  C07K16/46 ,  C12N15/85

Abstract: The disclosure provides antigen binding domains that bind cluster of differentiation 3 (CD3) protein, comprising the antigen binding domains that bind CD3ε, polynucleotides encoding them, vectors, host cells, methods of making and using them.

公开(公告)号：US11149094B2

公开(公告)日：2021-10-19

申请号：US15997222

申请日：2018-06-04

Applicant: Janssen Biotech, Inc.

Inventor： Mark Chiu ,  Adam Zwolak

IPC: C07K16/46 ,  C07K16/24 ,  C07K16/10 ,  C07K16/28

Abstract: The present invention relates to engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations and methods of making and using them.

公开(公告)号：US20180346605A1

公开(公告)日：2018-12-06

申请号：US15997222

申请日：2018-06-04

Applicant: Janssen Biotech, Inc.

Inventor： Mark Chiu ,  Adam Zwolak

IPC: C07K16/46

Abstract: The present invention relates to engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations and methods of making and using them.

公开(公告)号：US20250066510A1

公开(公告)日：2025-02-27

申请号：US18795538

申请日：2024-08-06

Applicant: Janssen Biotech, Inc.

Inventor： Jason Ho ,  Lijs Beke ,  Jinquan Luo ,  Elisabeth Prinslow ,  Adam Zwolak ,  Cholpon Tilegenova

IPC: C07K16/40 ,  A61P35/00 ,  C07K16/28

Abstract: Disclosed herein are antibodies or antigen binding fragments thereof that bind guanylyl cyclase C (GUCY2C), multi-specific antibodies comprising the same, and methods of treating cancer using the same.

公开(公告)号：US12134658B2

公开(公告)日：2024-11-05

申请号：US17391744

申请日：2021-08-02

Applicant: JANSSEN BIOTECH, INC.

Inventor： Rajkumar Ganesan ,  Adam Zwolak ,  Ian White ,  Ninkka Tamot ,  Paul B. Harvilla ,  Rajitha Doddareddy ,  Sanjaya Singh ,  Martin Jack Borrok, III

IPC: C07K16/40 ,  A61K39/00 ,  C07K16/10 ,  C07K16/28

Abstract: Provided herein are multispecific molecules comprising a first binding domain that specifically binds to polymeric immunoglobulin receptor (pIgR) and a second binding domain that specifically binds to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and related methods for the treatment of patients infected with SARS-CoV-2.